SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC14D9C - Written communication relating to third party tender offer:
SEC Accession No. 0001193125-24-196021
Filing Date
2024-08-07
Accepted
2024-08-07 17:10:25
Documents
1

Document Format Files

Seq Description Document Type Size
1 SC14D9C d856692dsc14d9c.htm SC14D9C 8240
  Complete submission text file 0001193125-24-196021.txt   10195
Mailing Address 700 PARK OFFICES DRIVE SUITE 200 RESEARCH TRIANGLE PARK NC 27709
Business Address 700 PARK OFFICES DRIVE SUITE 200 RESEARCH TRIANGLE PARK NC 27709 919-213-9835
G1 Therapeutics, Inc. (Filed by) CIK: 0001560241 (see all company filings)

IRS No.: 263648180 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC14D9C
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 700 PARK OFFICES DRIVE SUITE 200 RESEARCH TRIANGLE PARK NC 27709
Business Address 700 PARK OFFICES DRIVE SUITE 200 RESEARCH TRIANGLE PARK NC 27709 919-213-9835
G1 Therapeutics, Inc. (Subject) CIK: 0001560241 (see all company filings)

IRS No.: 263648180 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC14D9C | Act: 34 | File No.: 005-90214 | Film No.: 241184950
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)